A dual-label time-resolved fluorescence immunoassay (TRFIA) for screening of Coronary atherosclerosis based on simultaneous detection of Lp-PLA2 and HsCRP

Immunol Lett. 2017 Feb:182:12-17. doi: 10.1016/j.imlet.2016.12.004. Epub 2016 Dec 23.

Abstract

Atherosclerosis is the underlying cause of most coronary events. The conventional method for coronary atherosclerosis detection is morphological examination or coronary arterionyraphy. These methods are complex and time-consuming. In this study a two-step dual-label TRFIA was developed for the simultaneous detection of Lp-PLA2 and hsCRP in a single run. The performance of this assay was first evaluated using clinical serum samples, and then compared with commercialized kits. The sensitivity of this assay for Lp-PLA2 detection was 1ng/mL (dynamic range, 0-1000U/L), and the sensitivity for hsCRP detection was 1mg/L (dynamic range, 1-1000mg/L). High correlation coefficients (R) were obtained between the present dual-label TRFIA and commercially available kits(R=0.99 for LP-PLA2 and hsCRP). The present dual-label TRFIA has high sensitivity, specificity, and accuracy in clinical sample analysis. It is a good alternative to the single-label diagnostic methods.

Keywords: Coronary atherosclerosis; Dual-label TRFIA; LP-PLA2; hsCRP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Alkyl-2-acetylglycerophosphocholine Esterase / blood*
  • Atherosclerosis / blood*
  • Atherosclerosis / diagnosis*
  • Biomarkers
  • C-Reactive Protein*
  • Coronary Artery Disease / blood*
  • Coronary Artery Disease / diagnosis*
  • Fluoroimmunoassay / methods*
  • Humans
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • Biomarkers
  • C-Reactive Protein
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase